GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Latest Information Update: 07 Jan 2024
At a glance
- Drugs GSK 2302032A (Primary) ; AS15
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PEARL; PRAME-AS15-NSC-002 (ADJ)
- Sponsors GlaxoSmithKline; GSK
- 17 Oct 2016 Status changed from active, no longer recruiting to completed.
- 05 Sep 2014 Planned End Date changed from 1 Jan 2020 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
- 05 Sep 2014 Planned primary completion date changed from 1 Jan 2020 to 1 Sep 2016 as reported by ClinicalTrials.gov record.